|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Neuropathic Low Back Pain - Off-label Revenue Despite Diagnostic Challenge
Datamonitor, June 2004, Pages: 120
Introduction
Despite millions of patients worldwide, not one neuropathic pain drug company is prioritizing the neuropathic low back pain (NLBP) market. The problem is simply that this patient group is difficult to define in clinical practice. Once diagnosis is made, however, physicians commonly prescribe recognized neuropathic pain drugs, thus NLBP offers a significant source of off-label drug sales in the US.
Scope
- Quantitative treatment data from over 384 physicians from the US, Japan, France, Germany, Italy, Spain, and the UK
- Analysis of epidemiology, assessment and referral patterns, and first- to third-line treatments
- Discussion of the market need for more evidence-based treatments, improved diagnosis and identification of treatment responders
- Coverage of the hot topics including the use of opioids, the upcoming launch of pregabalin
Highlights
- Neuropathic low back pain affects an estimated 5.6 million people in the US alone. However, this type of back pain is rarely diagnosed and is poorly treated in the primary care setting. As such, there is strong need to educate physicians, especially PCPs, about the difference between the types of low back pain.
- There is little consensus as to best treatment practice between countries and even between physician types, which is compounded by the heterogeneity of patients and a dearth of randomized controlled trial data. A company can grow its share of the market by providing clear, convincing scientific data as either monotherapy or combination.
- The future market is not entirely the reserve of generic companies and Pfizer. A significant commercial opportunity exists for medical device companies, although the biggest challenge is to change the physician perception that interventional treatment of NLBP is a modestly effective last resort.
Reasons to Purchase
- Forecast product sales by understanding key aspects of NLBP epidemiology, referral, diagnosis, treatment, and unmet needs
- Improve pain product positioning strategies by identifying the commercial opportunities offered by the NLBP niche
- Understand why this untapped market warrants pharmaceutical industry interest
Customers who bought this item also bought
Stakeholder Insight: HIV Related Neuropathic Pain - Useful Niche for Peripheral Companies
Stakeholder Insight: Diabetic Neuropathic Pain - Market Success is Not Limited to Pregabalin
Postoperative Pain: Dynastat Cutting Up The Pain Market
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail To Nail Neuropathic Pain
Neuropathic Pain Insight - Life Beyond Gabapentin
Strategic Perspectives 2001: Neuropathic pain - Catch 22: high revenue potential but a high risk investment
Pain Therapeutics - Drugs, Markets and Companies
Stakeholder Insight: Neuropathic Pain - Comparative Overview of Treatment Preferences Across the Seven Major Markets
|
|
|
|
